fludarabine and Neoplasms

fludarabine has been researched along with Neoplasms in 48 studies

Research

Studies (48)

TimeframeStudies, this research(%)All Research%
pre-19902 (4.17)18.7374
1990's4 (8.33)18.2507
2000's25 (52.08)29.6817
2010's14 (29.17)24.3611
2020's3 (6.25)2.80

Authors

AuthorsStudies
Almazi, JG; Alomari, M; Belov, L; Best, OG; Christopherson, RI; Graham, ME; Mulligan, SP; Shen, Y1
Fan, X; Hu, J; Tang, W; Wang, L1
Angelucci, E; Arcese, W; Battipaglia, G; Blaise, D; Chalandon, Y; Chiusolo, P; Contentin, N; Czerw, T; de Wreede, LC; Fanin, R; Fox, ML; Hayden, P; Hernandez-Boluda, JC; Iori, AP; Kroger, N; Marotta, G; Mauff, K; McLornan, D; Mohty, M; Pioltelli, P; Rubio, MT; Santarone, S; Sever, M; Solano, C; Wendel, L; Yakoub-Agha, I1
Cros-Perrial, E; Dumontet, C; Jordheim, LP; Lefebvre-Tournier, I; Peyrottes, S; Puy, JY1
Austin, E; Burt, DJ; Byatte, AJ; Chester, KA; Gilham, DE; Guest, RD; Halford, SER; Hawkins, RE; Kirillova, N; Nabarro, S; Pillai, M; Rothwell, DG; Sharma, SK; Thistlethwaite, FC; Valle, JW; Wan, S; Westwood, NB1
Schmidt, C1
Abedin, S; Choi, S; Couriel, DR; Levine, JE; Peres, E; Yanik, G1
Nishikawa, H1
Allan, PW; Carroll, WR; Chung, TK; Clemons, L; Conry, RM; Hong, J; Hunt, FR; Lowman, D; Mannion, K; Nabell, L; Parker, WB; Richman, J; Rosenthal, EL; Sorscher, EJ1
Choi, ES; Im, HJ; Jang, S; Koh, KN; Kwon, SW; Lee, SW; Park, CJ; Seo, JJ; Suh, JK1
Beyer, M; Dietrich, S; Göder, A; Heinzel, T; Kiweler, N; Krämer, OH; Linnebacher, M; Mahboobi, S; Mahendrarajah, N; Nikolova, T; Rauch, A; Reich, TR; Schäfer, C; Schneider, G; Sellmer, A; Sonnemann, J; Stojanovic, N; Tomicic, MT; Wieczorek, M1
van der Griend, R; van der Spek, E1
Atkinson, K; Burns, AM; Hart, DN; Kambouris, ME; Lange, J; Lourie, R; Munster, DJ; Rice, AM; Sinfield, L; Turner, BE1
Cao, TM; Franke, GN; Gyurkocza, B; Hoppe, R; Lange, T; Leisenring, W; Maloney, DG; Negrin, RS; Sandmaier, BM; Shizuru, JA; Sorror, M; Storb, RF1
de Rezende, LC; Guimarães, MC; Rangel, LB; Silva, IV1
Costello, R; Csako, G; Langan, RC; Prieto, PA; Rosenberg, SA; Sherry, RM; White, DE; Wunderlich, J; Yang, JC; Zlott, D1
Baxter-Lowe, LA; Bhatia, M; Bradley, MB; Cairo, MS; Della-Latta, P; Freedman, J; Garvin, JH; George, D; Geyer, MB; Harrison, L; Jacobson, JS; Moore, V; Morris, E; Satwani, P; Schwartz, J; van de Ven, C1
Dallas, MH; Hartford, C; Laver, J; Leung, W; Pillai, A; Shook, DR; Srinivasan, A; Triplett, BM1
Blaise, D; Castagna, L1
Diker-Cohen, T; Lahav, M; Natur, A; Shapira, H; Szyper-Kravitz, M; Uziel, O1
Bos, GM; Huugen, D; Jansen, M; Jansen, R; Lalisang, R; Schouten, HC; Wagstaff, J1
Chao, NJ; Clay, TM; Hobeika, AC; Lyerly, HK; Morse, MA; Mosca, PJ; Rizzieri, D; Stenzel, TT; Vredenburgh, JJ1
Balzarotti, M; Bertuzzi, A; Castagna, L; Farè, M; Grimoldi, MG; Magagnoli, M; Nozza, A; Santoro, A; Sarina, B; Sinnone, M; Siracusano, L; Timofeeva, I1
Bay, JO; Bilger, K; Blaise, D; Chabannon, C; Choufi, B; Coso, D; Faucher, C; Maraninchi, D; Mohty, M; Stoppa, AM; Tournilhac, O; Vey, N; Viens, P1
Bravo-Hernández, G; Estrada, E; Gómez-Rangel, D; López-Martínez, B; Manuel Hernández, J; Marín-López, A; Ruiz-Argüelles, GJ1
Bardou, VJ; Bay, JO; Bilger, K; Blaise, D; Boiron, JM; Braud, AC; Cahn, JY; Chabannon, C; Choufi, B; Faucher, C; Fleury, J; François, S; Gratecos, N; Gravis, G; Maraninchi, D; Michallet, M; Mohty, M; Sotto, JJ; Viens, P; Viret, F1
Ackerstein, A; Bitan, M; Elad, S; Miron, S; Or, R; Resnick, IB; Samuel, S; Shapira, MY; Slavin, S; Zilberman, I1
Hamaki, T; Heike, Y; Hori, A; Kami, M; Kim, SW; Kishi, Y; Kojima, R; Kusumi, E; Masuo, S; Miyakoshi, S; Mori, S; Morinaga, S; Murashige, N; Muto, Y; Takaue, Y; Taniguchi, S; Tanosaki, R; Ueyama, J; Yuji, K1
Barrett, AJ; Childs, R; Donohue, T; Espinoza-Delgado, I; Geller, N; Gorak, E; Srinivasan, R; Suffredini, A1
Abidi, MH; Alangaden, G; Chandrasekar, PH; Heilbrun, LK; Klein, JL; Mellon-Reppen, S; Narreddy, S; Peres, E; Smith, D1
Bertetto, O; Busca, A; de Fabritiis, P; Falda, M; Locatelli, F; Novarino, A; Picardi, A; Zeuli, M1
Appelbaum, FR; Bedalov, A; Bryant, EM; Chang, C; Clurman, BE; Deeg, HJ; Flowers, ME; Hansen, JA; Nash, RA; Sanders, JE; Sandmaier, BM; Scott, BL; Shulman, HM; Storb, R; Storer, BE; Witherspoon, RP1
Gojkovic, Z; Hasholt, L; Joergensen, T; Knecht, W; Le Breton, C; Munch-Petersen, B; Piskur, J; Rozpedowska, E; Sandrini, MP; Willer, M1
Ding, W; Meng, H; Ni, W; Qian, W; Yang, C; Yang, X1
Baron, F; Beguin, Y; Castermans, E; Cheynier, R; Geenen, V; Gothot, A; Herens, C; Meuris, N; Schaaf-Lafontaine, N; Seidel, L; Vanbellighen, JF; Willems, E1
Clark, G; Hersh, M; Hutton, JJ; Kuhn, J; Phillips, J; Von Hoff, DD1
Faulds, D; McTavish, D; Ross, SR1
Estey, E; Gandhi, V; Gregoire, V; Huang, P; Keating, MJ; Plunkett, W; Robertson, LE; Yang, LY1
Bornhäuser, M; Ehninger, G; Freiberg-Richter, J; Helwig, A; Kroschinsky, F; Naumann, R; Neubauer, A; Platzbecker, U; Plettig, R; Röllig, C; Schuler, U; Thiede, C1
Vastag, B1
Delannoy, A; Feremans, W; Ferrant, A; Michaux, L; Van Den Neste, E1
Blume, KG; Chauncey, T; Feinstein, L; Flowers, C; Georges, G; Kiem, HP; Little, MT; Maloney, D; Maris, M; McSweeney, PA; Nash, RA; Niederwieser, D; Radich, J; Sandmaier, B; Shizuru, J; Storb, R; Woolfrey, A; Zaucha, JM1
Bornhäuser, M; Ehninger, G; Freiberg-Richter, J; Geissler, G; Helwig, A; Jenke, A; Lutterbeck, K; Oelschlagel, U; Platzbecker, U; Plettig, R; Röllig, C; Thiede, C1
Sallah, S; Wan, JY1
Da Prada, GA; Della Cuna, GR; Giorgiani, G; Giraldi, E; Landonio, G; Locatelli, F; Pedrazzoli, P; Schiavo, R; Siena, S; Zambelli, A1
Grever, MR; Malspeis, L; Staubus, AE; Young, D1
Finley, RS; Hood, MA1
Hutton, JJ; Von Hoff, DD1

Reviews

8 review(s) available for fludarabine and Neoplasms

ArticleYear
[Regulatory T cells in cancer immunotherapy].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:10

    Topics: Antibodies, Monoclonal; CD4-Positive T-Lymphocytes; CTLA-4 Antigen; Cyclophosphamide; Humans; Immune Tolerance; Immunosuppressive Agents; Immunotherapy; Ipilimumab; Molecular Targeted Therapy; Neoplasms; Programmed Cell Death 1 Receptor; Receptors, CCR4; T-Lymphocytes, Regulatory; Vidarabine

2014
Regulatory T cell as a target for cancer therapy.
    Archivum immunologiae et therapiae experimentalis, 2010, Volume: 58, Issue:3

    Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Cyclophosphamide; Humans; Immunotherapy; Lenalidomide; Mice; Models, Animal; Myeloablative Agonists; Neoplasms; T-Lymphocytes, Regulatory; Thalidomide; Vidarabine

2010
Do different conditioning regimens really make a difference?
    Hematology. American Society of Hematology. Education Program, 2012, Volume: 2012

    Topics: Adult; Aged; Bone Marrow Transplantation; Busulfan; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunotherapy; Medical Oncology; Middle Aged; Neoplasms; Stem Cell Transplantation; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2012
Fludarabine. A review of its pharmacological properties and therapeutic potential in malignancy.
    Drugs, 1993, Volume: 45, Issue:5

    Topics: Animals; Antineoplastic Agents; Humans; Neoplasms; Neoplasms, Experimental; Vidarabine

1993
Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies.
    Seminars in oncology, 1993, Volume: 20, Issue:5 Suppl 7

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Humans; Neoplasms; Vidarabine

1993
Second primary tumors and immune phenomena after fludarabine or 2-chloro-2'-deoxyadenosine treatment.
    Leukemia & lymphoma, 2001, Volume: 40, Issue:5-6

    Topics: Antineoplastic Agents; Autoimmunity; Cladribine; Humans; Immunosuppressive Agents; Neoplasms; Neoplasms, Second Primary; Vidarabine

2001
Nonmyeloablative hematopoietic cell transplantation. Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect.
    Annals of the New York Academy of Sciences, 2001, Volume: 938

    Topics: Adult; Animals; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclosporine; Disease Progression; Dogs; Forecasting; Graft Enhancement, Immunologic; Graft Survival; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Histocompatibility; Humans; Immunosuppressive Agents; Lymphocyte Transfusion; Methotrexate; Middle Aged; Mycophenolic Acid; Neoplasms; Prednisone; Radiation Chimera; T-Lymphocytes, Cytotoxic; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2001
Fludarabine: a review.
    DICP : the annals of pharmacotherapy, 1991, Volume: 25, Issue:5

    Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Evaluation; Humans; Leukemia; Neoplasms; Remission Induction; Vidarabine

1991

Trials

9 trial(s) available for fludarabine and Neoplasms

ArticleYear
Fludarabine and intravenous busulfan conditioning with post-transplantation cyclophosphamide for allogeneic peripheral stem cell transplantation for adult patients with lymphoid malignancies: a prospective single-arm phase II study.
    Frontiers of medicine, 2021, Volume: 15, Issue:1

    Topics: Adult; Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Neoplasms; Peripheral Blood Stem Cell Transplantation; Pharmaceutical Preparations; Prospective Studies; Transplantation Conditioning; Vidarabine

2021
The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity.
    Cancer immunology, immunotherapy : CII, 2017, Volume: 66, Issue:11

    Topics: Abdominal Pain; Adult; Aged; Anemia; Carcinoembryonic Antigen; Cohort Studies; Cyclophosphamide; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; GPI-Linked Proteins; Humans; Immunotherapy, Adoptive; Interferon-gamma; Interleukin-6; Lung; Male; Middle Aged; Myeloablative Agonists; Neoplasms; Receptors, Antigen, T-Cell; T-Lymphocytes; Treatment Outcome; Vidarabine; Vomiting

2017
Double umbilical cord blood transplantation after novel myeloablative conditioning using a regimen of fludarabine, busulfan, and total lymphoid irradiation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:12

    Topics: Acute Disease; Adolescent; Adult; Aged; Busulfan; Child; Child, Preschool; Chronic Disease; Cord Blood Stem Cell Transplantation; Disease-Free Survival; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Hematologic Diseases; Humans; Incidence; Infant; Infant, Newborn; Male; Middle Aged; Myeloablative Agonists; Neoplasms; Pilot Projects; Survival Rate; Time Factors; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2014
Phase I dose-escalating trial of Escherichia coli purine nucleoside phosphorylase and fludarabine gene therapy for advanced solid tumors.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:7

    Topics: Adenoviridae; Aged; Aged, 80 and over; Combined Modality Therapy; Dose-Response Relationship, Drug; Escherichia coli; Female; Follow-Up Studies; Genetic Therapy; Genetic Vectors; Humans; Injections, Intralesional; Male; Middle Aged; Neoplasm Staging; Neoplasms; Prognosis; Purine-Nucleoside Phosphorylase; Tumor Cells, Cultured; Vidarabine

2015
Reduced intensity conditioning regimen followed by glycosylated G-CSF mobilized PBSCT in patients with solid tumors and malignant lymphomas.
    Bone marrow transplantation, 2002, Volume: 30, Issue:4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Graft Survival; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Immunosuppressive Agents; Lymphoma; Male; Middle Aged; Neoplasms; Peripheral Blood Stem Cell Transplantation; Pilot Projects; Recombinant Proteins; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2002
A new minimally ablative stem cell transplantation procedure in high-risk patients not eligible for nonmyeloablative allogeneic bone marrow transplantation.
    Bone marrow transplantation, 2003, Volume: 32, Issue:6

    Topics: Adult; Busulfan; Cyclosporine; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Neoplasms; Patient Selection; Pilot Projects; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2003
Engraftment syndrome after nonmyeloablative allogeneic hematopoietic stem cell transplantation: incidence and effects on survival.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2005, Volume: 11, Issue:7

    Topics: Adult; Age Factors; Aged; Cyclophosphamide; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Incidence; Male; Middle Aged; Myelopoiesis; Neoplasms; Neutrophils; Risk Factors; Sex Factors; Syndrome; Transplantation Conditioning; Vidarabine

2005
Evidence for neo-generation of T cells by the thymus after non-myeloablative conditioning.
    Haematologica, 2008, Volume: 93, Issue:2

    Topics: Adult; Aged; Anesthesia Recovery Period; CD8-Positive T-Lymphocytes; Cyclosporine; Female; Flow Cytometry; Graft vs Host Disease; Histocompatibility Testing; Humans; Immunosuppressive Agents; Lymphocyte Depletion; Male; Middle Aged; Mycophenolic Acid; Myeloablative Agonists; Neoplasms; Peripheral Blood Stem Cell Transplantation; Receptors, Antigen, T-Cell, alpha-beta; Thymus Gland; Time Factors; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2008
Dose-reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:8

    Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Chronic Disease; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Killer Cells, Natural; Male; Middle Aged; Neoplasms; Pneumonia; Survival Analysis; Tissue Donors; Transplantation Conditioning; Treatment Outcome; Vidarabine

2001

Other Studies

31 other study(ies) available for fludarabine and Neoplasms

ArticleYear
Fludarabine nucleoside induces major changes in the p53 interactome in human B-lymphoid cancer cell lines.
    Nucleosides, nucleotides & nucleic acids, 2022, Volume: 41, Issue:3

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line; Cyclophosphamide; Humans; Neoplasms; Nucleosides; Tumor Suppressor Protein p53; Vidarabine

2022
Thiotepa-busulfan-fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT.
    Bone marrow transplantation, 2021, Volume: 56, Issue:7

    Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neoplasms; Primary Myelofibrosis; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine

2021
Determination and quantification of intracellular fludarabine triphosphate, cladribine triphosphate and clofarabine triphosphate by LC-MS/MS in human cancer cells.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2017, May-15, Volume: 1053

    Topics: Adenine Nucleotides; Adenosine Triphosphate; Antineoplastic Agents; Arabinonucleosides; Cell Line, Tumor; Chromatography, High Pressure Liquid; Cladribine; Clofarabine; Humans; Limit of Detection; Neoplasms; Polyphosphates; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Vidarabine

2017
The struggle to do no harm in clinical trials.
    Nature, 2017, 12-21, Volume: 552, Issue:7685

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD19; Child; Clinical Trials as Topic; Drug-Related Side Effects and Adverse Reactions; Humans; Immunotherapy; Inflammation; Lenalidomide; Male; Neoplasms; Nivolumab; Prognosis; Programmed Cell Death 1 Receptor; Risk Management; T-Lymphocytes; Thalidomide; Treatment Outcome; Vidarabine

2017
Haploidentical HCT using an αβ T-cell-depleted graft with targeted αβ(+) cells by add-back after a reduced intensity preparative regimen containing low-dose TBI.
    Bone marrow transplantation, 2016, Volume: 51, Issue:9

    Topics: Adolescent; Antilymphocyte Serum; Child; Child, Preschool; Cyclophosphamide; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Humans; Infant; Lymphocyte Depletion; Male; Neoplasms; Receptors, Antigen, T-Cell, alpha-beta; Survival Analysis; T-Lymphocytes; Transplantation Conditioning; Transplantation, Haploidentical; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult

2016
Class I histone deacetylases regulate p53/NF-κB crosstalk in cancer cells.
    Cellular signalling, 2017, Volume: 29

    Topics: Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cellular Senescence; DNA Damage; DNA, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxyurea; Models, Biological; Mutation; Neoplasms; NF-kappa B; Signal Transduction; Tumor Suppressor Protein p53; Vidarabine

2017
Comment to: Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study. Haematologica 2008; 93:398-403.
    Haematologica, 2008, Volume: 93, Issue:7

    Topics: Aged; Antineoplastic Agents; Databases, Factual; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasms; Neoplasms, Second Primary; Research Design; Sex Factors; Time Factors; Treatment Outcome; Vidarabine

2008
Reduced intensity conditioning for allogeneic hematopoietic stem-cell transplant determines the kinetics of acute graft-versus-host disease.
    Transplantation, 2008, Oct-15, Volume: 86, Issue:7

    Topics: Animals; Cyclophosphamide; Drug Administration Schedule; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Injections, Intraperitoneal; Kinetics; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasms; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2008
Salvage allogeneic hematopoietic cell transplantation with fludarabine and low-dose total body irradiation after rejection of first allografts.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2009, Volume: 15, Issue:10

    Topics: Acute Disease; Adolescent; Adult; Aged; Anemia, Aplastic; Child; Chronic Disease; Female; Follow-Up Studies; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Living Donors; Male; Middle Aged; Myeloablative Agonists; Neoplasms; Recurrence; Retrospective Studies; Salvage Therapy; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2009
Assessment of ovarian function after preparative chemotherapy and total body radiation for adoptive cell therapy.
    Journal of immunotherapy (Hagerstown, Md. : 1997), 2011, Volume: 34, Issue:4

    Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Follicle Stimulating Hormone; Humans; Immunotherapy, Adoptive; Middle Aged; Neoplasms; Ovary; Primary Ovarian Insufficiency; Radiotherapy; Retrospective Studies; Treatment Outcome; Vidarabine; Young Adult

2011
A comparison of immune reconstitution and graft-versus-host disease following myeloablative conditioning versus reduced toxicity conditioning and umbilical cord blood transplantation in paediatric recipients.
    British journal of haematology, 2011, Volume: 155, Issue:2

    Topics: Alemtuzumab; Antibiotic Prophylaxis; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Female; Genetic Diseases, Inborn; Graft Survival; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukocyte Count; Male; Melphalan; Myeloablative Agonists; Neoplasms; Neutrophils; Recombinant Proteins; Retrospective Studies; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2011
Successful allogeneic hematopoietic cell engraftment after a minimal conditioning regimen in children with relapsed or refractory solid tumors.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:2

    Topics: Adolescent; Adult; Child; Child, Preschool; Chimerism; Hematopoietic Stem Cell Transplantation; Humans; Neoplasms; Recurrence; Remission Induction; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation; Young Adult

2013
The effect of chemotherapy on telomere dynamics: clinical results and possible mechanisms.
    Leukemia & lymphoma, 2013, Volume: 54, Issue:9

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Female; Fluorouracil; Hematopoietic Stem Cells; Humans; In Situ Hybridization, Fluorescence; Karyotype; Male; Middle Aged; Neoplasms; Telomere; Vidarabine

2013
Non-myeloablative allogeneic stem cell transplantation in patients with solid tumours and patients with a haematological malignancy.
    The Netherlands journal of medicine, 2002, Volume: 60, Issue:4

    Topics: Adult; Cyclophosphamide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Neoplasms; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2002
Dendritic cell recovery following nonmyeloablative allogeneic stem cell transplants.
    Journal of hematotherapy & stem cell research, 2002, Volume: 11, Issue:4

    Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD; Antineoplastic Agents; Dendritic Cells; Flow Cytometry; Fluorescent Antibody Technique; Hematologic Diseases; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Myelodysplastic Syndromes; Neoplasms; Stem Cell Transplantation; Time Factors; Transplantation Chimera; Transplantation, Homologous; Vidarabine

2002
Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen.
    Blood, 2003, Jul-15, Volume: 102, Issue:2

    Topics: Acute Disease; Adolescent; Adult; Antilymphocyte Serum; Busulfan; Chronic Disease; Disease Progression; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Histocompatibility; Humans; Immunosuppressive Agents; Incidence; Life Tables; Lymphocyte Transfusion; Male; Middle Aged; Neoplasms; Peripheral Blood Stem Cell Transplantation; Recurrence; Risk Factors; Siblings; Survival Analysis; T-Lymphocytes; Tissue Donors; Transplantation Conditioning; Treatment Outcome; Vidarabine

2003
Decreased transfusion requirements in patients given stem cell allografts using a non-myeloablative conditioning regimen: a single institution experience.
    Hematology (Amsterdam, Netherlands), 2003, Volume: 8, Issue:3

    Topics: Adolescent; Adult; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Erythrocyte Transfusion; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hematopoietic Stem Cell Mobilization; Humans; Male; Methotrexate; Middle Aged; Neoplasms; Peripheral Blood Stem Cell Transplantation; Platelet Transfusion; Prospective Studies; Recombinant Proteins; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2003
Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors.
    Blood, 2004, Jan-15, Volume: 103, Issue:2

    Topics: Acute Disease; Adult; Antilymphocyte Serum; Bone Marrow Transplantation; Busulfan; Chronic Disease; Disease Progression; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Siblings; Stem Cell Transplantation; Survival Analysis; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2004
Feasibility of reduced intensity hematopoietic stem cell transplantation from an HLA-matched unrelated donor.
    Bone marrow transplantation, 2004, Volume: 33, Issue:7

    Topics: Adult; Aged; Antilymphocyte Serum; Bone Marrow Transplantation; Cladribine; Feasibility Studies; Female; Graft vs Host Disease; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Histocompatibility; Histocompatibility Testing; Humans; Male; Middle Aged; Neoplasms; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation Immunology; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2004
Non-bacterial infections in allogeneic non-myeloablative stem cell transplant recipients.
    Transplant infectious disease : an official journal of the Transplantation Society, 2007, Volume: 9, Issue:1

    Topics: Academies and Institutes; Antineoplastic Agents; Aspergillosis; Cyclophosphamide; Cytomegalovirus Infections; Drug Therapy, Combination; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Michigan; Middle Aged; Myeloablative Agonists; Neoplasms; Opportunistic Infections; Retrospective Studies; Review Literature as Topic; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2007
Nonmyeloablative allogeneic blood stem cell transplantation in patients with metastatic solid tumors.
    Hematology (Amsterdam, Netherlands), 2006, Volume: 11, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Renal Cell; Colonic Neoplasms; Feasibility Studies; Female; Graft Survival; Graft vs Host Disease; Graft vs Tumor Effect; Humans; Immunosuppressive Agents; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Peripheral Blood Stem Cell Transplantation; Postoperative Complications; Rectal Neoplasms; Sarcoma; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2006
Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic d
    Blood, 2007, Aug-15, Volume: 110, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Cohort Studies; Cyclophosphamide; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms; Neoplasms, Second Primary; Prognosis; Survival Rate; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2007
Drosophila deoxyribonucleoside kinase mutants with enhanced ability to phosphorylate purine analogs.
    Gene therapy, 2007, Volume: 14, Issue:17

    Topics: Animals; Antimetabolites; Antineoplastic Agents; Cell Line, Tumor; Cladribine; Cytarabine; Directed Molecular Evolution; Drosophila melanogaster; Genes, Transgenic, Suicide; Genetic Therapy; Glioblastoma; Humans; Lethal Dose 50; Mutation; Neoplasms; Osteosarcoma; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Purines; Substrate Specificity; Transduction, Genetic; Vidarabine

2007
Antitumor activity of fludarabine against human multiple myeloma in vitro and in vivo.
    European journal of haematology, 2007, Volume: 79, Issue:6

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Dexamethasone; Female; Gene Expression Regulation, Neoplastic; Humans; In Vitro Techniques; Inhibitory Concentration 50; Mice; Mice, SCID; Multiple Myeloma; Neoplasm Transplantation; Neoplasms; Vidarabine

2007
Phase I clinical investigation of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate (NSC 312887), a new purine antimetabolite.
    Cancer research, 1984, Volume: 44, Issue:9

    Topics: Adenocarcinoma; Arabinonucleotides; Drug Evaluation; Female; Humans; Kinetics; Lung Neoplasms; Male; Neoplasms; Vidarabine; Vidarabine Phosphate

1984
Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin.
    Bone marrow transplantation, 2000, Volume: 26, Issue:2

    Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Agents; Busulfan; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infections; Male; Middle Aged; Neoplasms; Nuclear Family; Prospective Studies; Recurrence; Survival Rate; T-Lymphocytes; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2000
A brief history of the brief history of low-dose transplants.
    Journal of the National Cancer Institute, 2000, Aug-02, Volume: 92, Issue:15

    Topics: Antineoplastic Agents; Bone Marrow Transplantation; History, 20th Century; Humans; Immunosuppressive Agents; Neoplasms; United States; Vidarabine

2000
Inhibitors against factor VIII associated with the use of interferon-alpha and fludarabine.
    Thrombosis and haemostasis, 2001, Volume: 86, Issue:4

    Topics: Adult; Autoantibodies; Factor VIII; Female; Hemorrhagic Disorders; Humans; Interferon-alpha; Male; Middle Aged; Neoplasms; Partial Thromboplastin Time; Vidarabine

2001
Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies.
    Cancer, 2002, May-01, Volume: 94, Issue:9

    Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Breast Neoplasms; Carcinoma, Renal Cell; Child; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Kidney Neoplasms; Male; Melanoma; Middle Aged; Neoplasms; Pilot Projects; Sarcoma; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2002
Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate.
    Seminars in oncology, 1990, Volume: 17, Issue:5 Suppl 8

    Topics: Antimetabolites, Antineoplastic; Chromatography, High Pressure Liquid; Drug Evaluation; Humans; Injections, Intravenous; Multivariate Analysis; Neoplasms; Vidarabine; Vidarabine Phosphate

1990
Cytotoxicity of 2-chlorodeoxyadenosine in a human tumor colony-forming assay.
    Cancer drug delivery, 1986,Spring, Volume: 3, Issue:2

    Topics: Cell Survival; Cells, Cultured; Cladribine; Colony-Forming Units Assay; Deoxyadenosines; Drug Evaluation, Preclinical; Female; Humans; Kinetics; Neoplasms; Vidarabine

1986